Evidence map›Paper›PMID 42405774›Full record

ArticleJournal of virology2026

Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.

Pramila Lamichhane, Lijuan Yang, Celia Santos, Hong-Su Park, Li Ou, Tongqing Zhou, Cyril Le Nouën, Ursula J Buchholz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pramila LamichhaneRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Lijuan YangRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Celia SantosRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Hong-Su ParkRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Li OuVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.
Tongqing ZhouVaccine Research Center, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-3935-4637
Cyril Le NouënRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-5719-4112
Ursula J BuchholzRNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-2329-3198

Funding

Laboratory Studies of Human Respiratory Syncytial Virus and Other PneumovirusesZIAAI000372 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BUCHHOLZ, URSULA · 2009 to 2025
$21.8M
Design Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5M
Intramural NIH HHS ZIA AI000372Intramural NIH HHS ZIA AI005024NIH HHS ZIA AI000372NIH HHS ZIA AI005024Sanofi Cooperative Research and Development Agreement
6 · The paper itself

Abstract

Human metapneumovirus (HMPV, genus IMPORTANCE: Human metapneumovirus (HMPV) is a leading cause of lower respiratory illness in young children, and there are no licensed vaccines. Similarly to immunization strategies against the related human respiratory syncytial virus (HRSV), live-attenuated HMPV vaccines for intranasal immunization would be most suitable for young children. Live-intranasal vaccines infect and induce immunity in the presence of residual maternal antibodies without priming for enhanced respiratory disease. Genetic stability of attenuating mutations represents a challenge in vaccine design. We generated live-attenuated HMPV vaccine candidates by introducing into corresponding sites of the HMPV polymerase gene temperature-sensitivity-inducing attenuating mutations that had been originally developed for HRSV, genetically stabilized, and proven to be free of reversions in HRSV vaccine studies. The resulting HMPV vaccine candidates are temperature-sensitive, attenuated, and genetically stable under temperature stress. In the hamster model, the new HMPV candidates were immunogenic and protective. These live-attenuated HMPV candidates will be advanced to pediatric vaccine studies.

Indexed as

MetapneumovirusMutationParamyxoviridae InfectionsRespiratory Syncytial Virus, HumanViral VaccinesAnimalsChlorocebus aethiopsHumansRespiratory Syncytial Virus InfectionsTemperatureVaccines, AttenuatedVero CellsVirus ReplicationVaccines, AttenuatedViral Vaccineshuman metapneumovirusintranasal immunizationlive-attenuated vaccinetemperature sensitivity

Identifiers

PMID42405774
PMCPMC13483368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.